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Immature T cell lymphomas represent a sig­
nificant portion of human lymphoid malig­
nancies (Ferrando and Look, 2000; Armstrong 
and Look, 2005). Approximately 50% of these   
tumors harbor recurrent chromosomal translo­
cations (Aifantis et al., 2008), which likely arise 
through errors in the repair of DNA double­
strand breaks (DSBs). In this context, normal 
mouse  and  human  thymocyte  differentiation 
requires V(D)J recombination, a process that in­
volves the introduction of DSBs at T cell recep­
tor (Tcr) loci by the recombination­activating 
gene (RAG) 1 and 2 endonuclease (Bassing   
et al., 2002). If such programmed Tcr DSBs are 
repaired incorrectly, they can generate chro­
mosomal translocations that involve Tcr loci. In 
fact, 70% of recurrent translocations in human 
T cell acute lymphoblastic leukemias (T­ALL) 
involve TCR loci (Aifantis et al., 2008). Fur­
thermore, RAG­initiated DSBs in and around 
T cell oncogene loci may also contribute to 
clonal translocations in T cell lymphoma (Aifantis 
et al., 2008). In addition, developing T cells are 
also subject to general DSBs that occur during 
S phase in association with periods of rapid cel­
lular division. These DSBs apparently can occur 
in numerous chromosomal locations, and po­
tentially participate in Tcr locus­related translo­
cations (Bassing et al., 2003).
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Ataxia telangiectasia mutated (ATM) deficiency predisposes humans and mice to T lineage 
lymphomas with recurrent chromosome 14 translocations involving the T cell receptor / 
(Tcra/d ) locus. Such translocations have been thought to result from aberrant repair of 
DNA double-strand breaks (DSBs) during Tcra locus V(D)J recombination, and to require the 
Tcra enhancer (E) for Tcra rearrangement or expression of the translocated oncogene.  
We now show that, in addition to the known chromosome 14 translocation, ATM-deficient 
mouse thymic lymphomas routinely contain a centromeric fragment of chromosome 14 
that spans up to the 5 boundary of the Tcra/d locus, at which position a 500-kb or larger 
region centromeric to Tcra/d is routinely amplified. In addition, they routinely contain a 
large deletion of the telomeric end of one copy of chromosome 12. In contrast to prior 
expectations, the recurrent translocations and amplifications involve V(D)J recombination–
initiated breaks in the Tcrd locus, as opposed to the Tcra locus, and arise independently  
of the E. Overall, our studies reveal previously unexpected mechanisms that contribute  
to the oncogenic transformation of ATM-deficient T lineage cells.
©  2010  Zha  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first 
six  months  after  the  publication  date  (see  http://www.rupress.org/terms).   
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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characterized by immunodeficiency, genomic instability, and 
lymphoid malignancies (Lavin, 2008). Most T cell malig­
nancies in AT patients are T­ALLs, which have not been 
well characterized cytogenetically. However, older AT pa­
tients  who  harbor  clonal  expansions  of  peripheral  T  cells   
with  inv(14)(q11;q32),  t(14;14)(q11;32.1),  or  rarely, 
t(X;14)(q28;q11)  translocations,  sometimes  develop  T  cell 
prolymphocytic leukemia (T­PLL; Pekarsky et al., 2001). The 
inv(14)(q11;q32),  t(14;14)(q11;32.1),  or  t(X;14)(q28;q11) 
translocations appear to involve TCRA/D at 14q11 in hu­
mans and the T cell leukemia/lymphoma 1 (TCL1) (14q32.1) 
and MTCP1 (Xq28) oncogene loci, respectively (Russo   
et al., 1989; Fig. S1). ATM­deficient mice recapitulate aspects 
of human AT (Barlow et al., 1996; Elson et al., 1996; Xu   
et al., 1996; Herzog et al., 1998; Borghesani et al., 2000).   
In this regard, ATM­deficient mice have impaired thymocyte 
development with reduced CD3 expression on DP thymo­
cytes and decreased SP thymocyte numbers (Borghesani et al., 
2000; Huang et al., 2007), which is consistent with defective 
Tcra V(D)J recombination. Moreover, ATM­deficient mice 
succumb to DP thymic lymphomas with RAG­dependent 
translocations, which often join the Tcra/d on chromosome 
14 to the telomeric end of chromosome 12, where mouse 
Tcl1 is located. Thus, it has been speculated that the inv(14) 
or  t(14;14)  in  human  T­PLL  and  the  t(12;14)  in  mouse 
ATM­deficient thymic lymphoma both may activate TCL1 
or another dominant oncogene in this chromosomal region 
(Liyanage et al., 2000; Callén et al., 2009; Fig. S1).
We now characterize recurrent translocations in mouse 
ATM­deficient thymic lymphomas in depth and also test for 
roles of E in tumor development. Surprisingly, we find that 
the recurrent chromosome 14 translocations observed in ATM­
deficient thymic lymphomas are associated with V(D)J recom­
bination errors at Tcrd, as opposed to Tcra locus. In addition, we 
show that E is completely dispensable for the oncogenic 
processes leading to these tumors. Finally, we show that most 
of these tumors amplify a set of genes lying just upstream of 
the Tcra/d locus. Based on our findings, we propose a model 
for the generation of the recurrent genomic abnormalities in 
ATM­deficient thymic lymphomas (Fig. S1).
RESULTS
Recurrent amplification upstream of Tcra/d locus  
in ATM-deficient thymic lymphomas
We used comparative genomic hybridization (CGH) to assay 
for genomic alterations in DNAs prepared from 18 indepen­
dent thymic lymphomas that arose in mice homozygous for 
an ATM­inactivating mutation that we have previously de­
scribed (Borghesani et al., 2000). In addition to copy number 
losses associated with V(D)J recombination at Tcr, , /, 
or immunoglobulin heavy chain (Igh) loci, one of the most strik­
ing features of the CGH profiles of these tumors was the 
common amplification of chromosome 14 sequences. Notably, 
the telomeric end of the amplification region always began 
upstream of the Tcra J region segments, frequently within the 
Tcrd portion of the Tcra/d locus or, in a few cases, upstream (5) 
During T cell development in the thymus, TCR variable 
region gene exons are assembled by V(D)J recombination 
that is initiated by RAG­generated DSBs between V, D, and 
J segments and their flanking recombination signal sequences 
(RSSs; Rooney et al., 2004a). To complete V(D)J recombi­
nation, RAG­initiated coding sequence DSBs and RSS DSBs 
are joined to each other by the classical nonhomologous   
end­joining pathway (C­NHEJ; Rooney et al., 2004a; Lieber, 
2008). The V(D)J recombination process is also influenced 
by general DSB response factors such as the ataxia telangiec­
tasia mutated (ATM) protein (Liyanage et al., 2000; Bredemeyer 
et al., 2006; Callén et al., 2007; Huang et al., 2007). In humans 
and mice, the two distinct lineages of T lymphocytes are dis­
tinguished by the surface expression of either  or  TCRs 
(Bhandoola et al., 2007). TCR, , and  variable region 
exons are assembled in CD4/CD8 (double­negative) thy­
mocytes (von Boehmer, 2004). Productive VDJ and 
VJ rearrangements generate TCR  and  chains that form 
cell surface  TCR and prescribe  T cell expansion and 
development (Krangel et al., 1998). Productive VDJ re­
arrangements generate TCR chains, which, in conjunction 
with Notch1 signaling, promote differentiation to the CD4+/
CD8+ (double positive; DP) stage, in which Tcra rearrange­
ments occur (Garbe and von Boehmer, 2007). Productive 
VJ rearrangements generate TCR chains that associate 
with TCR and promote further differentiation to CD4+ or 
CD8+ single­positive (SP) mature T cells.
In both humans and mice, the TCRA and TCRD genes 
are encoded within the same locus (TCRA/D; Krangel et al., 
2004). The mouse Tcra/d locus lies on chromosome 14,   
with the C exons, which lie at the 3 (telomeric) end of 
Tcra/d, being preceded upstream by 60 J segments (Krangel 
et al., 2004; Fig. S1). The C exons lie upstream of the J 
segments and are flanked downstream by the V5 segment 
and upstream by a V4 segment, two D segments, and two 
J segments. Most V and V segments lie upstream of V4 
with V segments lying at the distal (5 or centromeric) end 
of the cluster, V/V segments in the center, and V segments 
at the downstream (telomeric) end (Krangel et al., 2004).   
Because of the unique Tcra/d organization, joining of V and 
J segments deletes the Tcrd portion of the locus (including 
C), permanently committing to the TCR/ lineage. V 
to J rearrangement requires the Tcra enhancer (E) at the 3 
end of Tcra/d locus (downstream of C) to promote V(D)J 
recombinational accessibility of J segments lying up to 
100­kb away (Sleckman et al., 1997). E also activates TCR 
expression (Sleckman et al., 1997). The human TCRA/D 
locus is similarly organized and lies on human chromosome 
14 (Fig. S1).
DNA  DSBs,  including  V(D)J  recombination  DSBs, 
activate the ATM kinase, which then phosphorylates sub­
strates involved in DNA repair and cell cycle control (Kastan   
et al., 2001). Although not required for V(D)J recombination, 
ATM helps promote normal DSB repair during this process   
(Bredemeyer  et  al.,  2006;  Callén  et  al.,  2007;  Huang   
et al., 2007). Human ATM mutations cause AT, which is   JEM VOL. 207, July 5, 2010 
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of the Tcra/d locus. In all cases, the amplification region we 
observed extended well beyond the centromeric end of the 
Tcra/d locus (Fig. 1 B and Fig. S2). We observed amplifica­
tion of this general region in all 18 Atm/ thymic lympho­
mas analyzed; albeit to differing extents of amplification and 
with amplicons in given tumors that ranged from 500 kb 
to >20 megabases (Mb; Fig. 1 B). The amplified sequences 
common to all tumors comprised an 500­kb genomic re­
gion that lies 10 Mb centromeric to the most 5 V of   
the Tcra/d locus (Fig. 1 B). We independently confirmed 
amplification of this region in multiple independent Atm/  
thymic lymphomas by performing Southern blotting analyses 
with probes derived from the commonly amplified 500­kb 
region (Fig. 1, B and C).
We found several other recurrent copy number changes, 
in addition to the recurrent amplifications, including hemi­
zygous deletion of the putative Bcl11b tumor suppressor gene 
(chromosome 12) in 21/23 cases (Fig. 1 A and Fig. S3, A–C), 
homozygous  deletion  of  the  Pten  tumor  suppressor  gene 
(chromosome 19) in 6/18 cases (Fig. 1 A and Fig. S1 C), and 
amplification of Notch1 oncogene (chromosome 2) in 5/18 
cases (Fig. 1 A and Fig. S2 B). The latter findings led us to   
sequence  the  coding  exons  of  Notch1  in  46  independent 
Atm/ thymic lymphomas, including 14 analyzed by CGH 
(including three Notch1­amplified tumors). We found Notch1 
mutations in 18/46 cases (39.1%; Fig. S3 D). Of the 20 muta­
tions found (2 out of 18 cases had two independent muta­
tions), 15 were proline/glutamic acid/serine/threonine­rich 
domain mutations (75%), and 5 were heterodimer domain 
mutations (25%; Fig. S3 D). Notably, the three Notch1­ 
amplified tumors sequenced (tumor 5534 [Fig. S3 B], 5696, 
and 6099) had no Notch1 mutations, suggesting that amplifi­
cation of Notch1 gene might act as an independent means of 
Notch1 activation in Atm/ thymic lymphomas.
The most frequent translocation in mouse ATM­deficient 
thymic lymphomas is a t(12;14) (Liyanage et al., 2000). To 
characterize  potential  relationships  between  the  recurrent 
gene  amplification  on  chromosome  14  and  this  recurrent 
translocation, we first used chromosome 12 and 14 paints to 
assay for chromosomal anomalies in metaphase spreads from 
individual Atm/ thymic lymphomas. Of 10 tumors ana­
lyzed, 7 had a clonal t(12;14), with clonality defined as the 
translocation occurring in 50% or more of the metaphases 
analyzed (Fig. 2 B, Fig. S4 B, and Table S1). Most meta­
phases also contained, in addition to the t(12;14), a chromo­
some 14 fragment, referred to as f(14), plus apparently normal 
chromosomes 14 and 12 (Fig. 2 C, Fig. S2, and Fig. S4 C). 
To further characterize potential anomalies, we stripped the 
paints from these metaphases and assayed them via fluores­
cence in situ hybridization (FISH) with a probe derived from 
the 3 (telomeric) end of the Tcra/d locus (C­Red; Liyanage 
et al., 2000) and a probe derived from the centromeric region 
of chromosome 14 (RP23_145L1; referred to as ch14cen­
Green; Fig. 2 C and Fig. S4 C). The t(12;14) retained sequences 
hybridizing to the C probe in the vicinity of the junction, 
but lacked ch14cen­hybridizing sequences (Fig. 2 C and   
Figure 1.  Amplification of sequences centromeric to the Tcra/d 
locus in Atm/ T cell lymphomas. (A) Combined CGH analysis of 18 
ATM-deficient thymic lymphomas. Each tumor sample was hybridized and 
analyzed once with matched kidney control DNA. The y axis represents 
amplification/deletion index (sum of LN tumor/kidney ratio of all tumors 
analyzed). Amplification and deletion were scored separately and plotted 
together. The amplification score at each probe location is plotted in red 
and deletion score is plotted in green. At some loci, such as the telomeric 
end of chromosome 12, both deletions and amplifications were found in 
this collection of tumors, which is termed copy number polymorphism, 
indicating inconsistent copy number changes in this region. The x axis 
depicts all 19 mouse chromosomes (1 to 19 arranged from centromere to 
telomere). The red arrows and text highlight recurrent amplifications of 
Notch1 and chromosome 14 sequences upstream of the Tcra/d locus, and 
as well as recurrent trisomy 15 (Tric15). The black arrows and text indicate 
the position of Tcr gene loci. The green arrows and text highlight recur-
rent deletions in the telomeric portion of chromosome 12 (tch12) and 
the Pten locus. (B) The diagram shows the length of amplification (defined 
by LN2 tumor/kidney > 0.667) in each of the ATM-deficient thymic lym-
phomas. The x axis is the base pair position indicated by distance (Mb) 
from the chromosome 14 centromere. The common amplification region 
is marked with a red box and shown in the expanded form at the bottom. 
The position of the BAC probe used for FISH (RP23_359O5) and probe 
used for Southern blotting are indicated. The Tcra/d locus is indicated 
with a filled blue box and expanded at the bottom of the panel to show 
relative orientation. (C) Southern blot analyses of 11 tumor/kidney DNA 
pairs. About 10 µg of genomic DNA from kidney (K) and the correspond-
ing tumors (T) was digested with EcoRI and probed with the probe  
described in B (Chr14 Amp) and with probes that recognize the Tcrd con-
stant region (C) or the Tcra (C). The red arrows indicate tumor samples 
with significant amplification. The blue arrowheads indicate the retention 
of C in those tumors. The asterisks mark the two samples that show C 
deletion as predicted by CGH analysis (Fig. 3 B). The loading control probe 
was derived from an intron of the Mdc1 gene (which lies on mouse chro-
mosome 17). M, DNA Marker; C, control DNA from 129sv mouse strain; 
B6, control DNA from BL6 mouse strain.1372 Genomic changes in ATM-deficient thymic lymphomas | Zha et al.
Fig. S4 C, second row, top), which is consistent with the 
t(12;14) resulting from fusion of the 3 region of the Tcra/d 
locus (including E) with chromosome 12. These analyses 
also revealed an apparently normal chromosome 14 that con­
tained both ch14cen and C­hybridizing sequences and a 
portion of chromosome 14 that contained the ch14cen­ 
hybridizing sequences but lacked C­hybridizing sequences 
(see following paragraph; Fig. 2 C and Fig. S4 C, second 
row, top). As would be expected, the normal chromosome 
12 did not hybridize to either C or ch14cen probes (Fig. 2 C 
and Fig. S4 C, second row, top). Finally, we stripped the 
slides and applied a probe from the center of the common 
amplification region (green; RP23_359O5, referred as Amp) 
and a C probe (red). In all eight samples tested, the C 
probe did not hybridize to f(14), whereas the Amp probe 
gave an intense signal on the f(14), which is consistent with 
amplification of these sequences in that location; however, 
no Amp probe signal was detected on the t(12;14) (Fig. 2 C 
and Fig. S4 C, third row, top; Table S1; see following para­
graph). Together, these latter results are consistent with the 
f(14) being a partner in the t(12;14) translocation (Fig. S2).
To unequivocally determine whether Tcra/d locus breaks 
contribute to the t(12;14) translocation, we prepared another set 
of metaphase spreads from 7 tumors with t(12:14) translocations 
and hybridized them with chromosome 12 (green) and chromo­
some 14 (red) paints first, and then stripped them and hybridized 
with the C probe (red) as well as a 5Tcra/d probe (green; 
RP23_304L21 derived from 6 kb upstream of the most 5V). 
In all seven sets of tumor metaphases analyzed, 5Tcra/d hybrid­
izing sequences were absent from the t(12;14) (Fig. 2 C and   
Fig. S4 C, middle), even though C­hybridizing sequences were   
retained near the junction (see previous paragraph; Table S1). 
Moreover, while C­hybridizing sequences were not observed 
on the 14(f) in any of the seven tumor samples, five of seven 
samples did contain 5Tcra/d hybridizing sequences on the   
14(f) (Fig. 2 C, Fig. S4 C, middle, and Table S2). Together, 
these findings suggest the t(12;14) was generated from breaks 
within the Tcra/d locus that split the locus into the t(12;14) and 
the 14(f). Finally, to look for a potential reciprocal t(14;12) trans­
location and to test if the telomeric portion of chromosome 12 
is lost during the t(12;14) translocation, we sequentially hybrid­
ized six independent sets of metaphases with chromosome 14   
plus chromosome 12 paints, and then a FISH probe derived from   
sequences just 3 (centromeric) to the Igh locus (199; red), which 
lies near the telomeric end of chromosome 12. Although the 
normal chromosome 12 in the metaphases always had a clear 
signal for the 3 Igh 199 probe, this probe did not hybridize to 
the t(12;14) translocation, indicating that the chromosome 12 
junctional region within the t(12;14) translocations in ATM­ 
deficient thymic lymphomas generally is located centromeric to 
the Igh locus (Fig. 2 C and Fig. S4 C, bottom, and Table S3).
ATM-deficient thymic lymphomas derive from cells that 
have not attempted Tcra rearrangement
Aberrant TCRA rearrangement has long been proposed as 
the cause for the recurrent chromosome 14 translocations in 
Figure 2.  Cytogenetic analysis of ATM-deficient thymic lympho-
mas. (A) Relative position of the 5Tcra/d (green), C (red), chr 14 Cen 
(green), and Amp (green) probes in relation to the Tcra/d locus on mouse 
chromosome 14. The colors of the lines indicating particular probes are 
consistent with the colors of these probes in C. (B) Representative chro-
mosome 14 (red) and chromosome 12 (green) paint analysis of a meta-
phase from an ATM-deficient thymic lymphoma shows a t(12;14) 
translocation (white arrow), two other chromosome 14 or chromosome 
14 fragments (red), and a chromosome 12 (green). Other representative 
analyses are shown in Fig. S4, and a summary of all slides analyzed is 
shown in Table S1. (C) Combined FISH and paint analyses of chromosomes 
14 and 12 (and their derivatives) from ATM-deficient thymic lymphomas. 
The color dedication of each row is marked by the color of the font indi-
cating the probes at the left. (top) One representative slide from tumor 
5534 that was hybridized with chromosome paint, stripped and rehybrid-
ized with C and ch14cen FISH, and then stripped and rehybridized with 
C and Amp FISH. (middle) Another representative slide from tumor 5534, 
which was hybridized with chromosome paint, stripped, and hybridized 
with C and 5Tcra/d probes. (bottom) Another representative slide from 
tumor 5534, which was first hybridized with chromosome paint, and then 
stripped and hybridized with Igh (199) FISH probe. Other representative 
analyses are shown in Fig. S4, and a summary of all slides analyzed is 
shown in Table S2. (D) Representative FISH analysis of using the Amp BAC 
(359O5 in green) and C BAC (in red) on metaphases from ATM-deficient 
thymic lymphomas. A white arrow indicates the amplified 359O5 signal 
and a yellow arrow indicates the isolated C. A pink arrow indicates the 
normal chromosome 14 containing both the Amp and C (without ampli-
fication) signals. Other representative analyses are shown in Fig. S4, and a 
summary of all slides analyzed is shown in Table S3. At least 10 (usually 
20) independent metaphases were scored for each tumor shown in the 
representative examples shown in this figure. The figures show results 
that were found in least 50% (often >85%) of the metaphases scored 
from each slides.JEM VOL. 207, July 5, 2010 
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but not Tcra rearrangement. To confirm the CGH result, we 
probed EcoRI­digested DNA from 11 representative Atm/ 
thymic lymphomas and corresponding kidneys with a probe 
from the C region and found that 9 out of 11 tumors re­
tained C, which in comparison to the kidney DNA signal 
appeared to be present bi­allelically in most tumors (Fig. 1 C). 
Notably, the Southern blot analysis also confirmed the ho­
mozygous deletion of C in the two cases predicted by CGH 
analysis (456 and 535; marked with an asterisk in Fig. 1 C and 
Fig. 3 B). As a control, all of the tumors analyzed (with the 
exception of tumor 277, in which the tumor DNA was sub­
stantially degraded) retained the C probe (Fig. 1 C). Together, 
these results indicate that ATM­deficient thymic lymphomas 
often derive from immature T cells that have not yet attempted 
Tcra rearrangement.
Molecular characterization of t(12;14) translocations  
in ATM-deficient thymic lymphomas
We used the high density CGH profile to analyze the chro­
mosome 12 status in 18 ATM­deficient thymic lymphomas. 
Consistent with loss of the 3Igh locus probe (199) from the 
t(12;14), as determined by FISH (Fig. 2 C and Fig. S4 C, 
bottom), and the absence of t(14;12) reciprocal transloca­
tions, the CGH analyses revealed that 14 of the 18 analyzed 
tumors had hemizygous deletions of the telomeric portion of   
chromosome 12 (Fig. 1 A and Fig. S3, A–C) with the deletions   
ranging from 5–30 Mb (Fig. 4 A). Copy number losses in 
high­density CGH analyses allowed us to roughly estimate 
the region of chromosome 12 containing the t(12;14) trans­
location junction in 23 Atm/ thymic lymphomas (includ­
ing 5 Atm/ tumors from mice that also lacked E, referred   
to as E/; see last section of Results). We found that t(12;14) 
translocation junctions in individual tumors were widely 
spread over an 28 Mb region of the telomeric portion of 
chromosome 12 (Fig. 4 A), regardless of E status (Fig. 4 A; 
filled triangles denote Atm/ tumors and open triangles de­
note E/Atm/ tumors).
The TCL1 oncogene, which is involved in some translo­
cations with the TCRA/D locus in T cell lymphomas from 
human AT patients, maps to mouse chromosome 12. Our 
CGH data indicate that many of the translocations (14 of 23) 
we have characterized in mouse Atm/ lymphomas involve 
chromosome 12 regions centromeric to Tcl1 and, thus, would 
delete the Tcl1 gene from the chromosome 12 involved in 
t(12;14) translocation, as previously found in analyses of a 
more limited set of tumors (Fig. 4 A; Liyanage et al., 2000). 
In this context, we verified that the t(12;14) translocations in 
four of six analyzed Atm/ thymic lymphomas lacked TCL1 
(Fig. S4 A). Likewise, array­based expression analysis of these 
six ATM­deficient thymic lymphomas indicated that Tcl1 
expression is not significantly different among lymphomas 
and normal thymocytes and similar in all lymphomas, whether 
or not Tcl1 was retained on the t(12;14) (Fig. S5 B). This is 
in contrast with the overexpression of TCL1 described in 
human patients with t(14;14) or inv(14) translocations (Chun 
et al., 2002). We also found that Bcl11b, which in some   
ATM­deficient thymic lymphomas (Callén et al., 2007; 
Huang et al., 2007; Liyanage et al., 2000). As most develop­
ing T lymphocytes in mice that rearrange the Tcra locus do so 
on both alleles and delete the Tcrd locus (Krangel et al., 2004), 
the hypothesis that recurrent chromosome 14 translocations 
in Atm/ thymic lymphomas involve aberrant Tcra locus re­
arrangements  would  imply  that  these  tumors  should  fre­
quently show bi­allelic deletions of, at least, a portion of J 
and complete deletion of the C region. To test this, we ana­
lyzed high­density CGH data in and around the vicinity of 
Tcra/d locus and found that 16 out of 18 ATM­deficient thymic 
lymphomas, in fact, retained the C region (Fig. 3, A and B), 
suggesting that the Atm/ thymic lymphomas derived from   
immature thymocytes that have not yet attempted Tcra re­
arrangement. Homozygous deletion of a particular genomic 
region is defined by an LN2 (CGH signal tumor/control kid­
ney) lower than 1.6 (Fig. 3 A). By this criterion, 16 out of 
the 18 Atm/ thymic lymphomas have homozygous deletions 
between the V4 and D2 segments, but not in other regions 
in the Tcra/d locus (Fig. 3, A and B), again suggestive of Tcrd 
Figure 3.  ATM-deficient thymic lymphomas usually arise from 
cells that have not attempted Tcra rearrangement. (A) High- 
resolution CGH data of the Tcra/d of six representative ATM-deficient 
thymic lymphomas. Each tumor sample was hybridized and analyzed with 
matched kidney control DNA. The y axis is the Log2 (tumor/kidney) ratio. 
The x axis is the megabase position of each probe from the chromosome 
14 centromere. The diagram at the bottom shows the relative position of 
the Tcra/d locus within this region. The homozygous deletion cut-off 
(Log2 [tumor/kidney] = 1.6) and heterozygous deletion cut-off (Log2 
(tumor/kidney) = −0.67) are marked in red. Each tumor is represented by a 
unique color, and the relative size of their deletions within the analyzed 
region is schematically represented by a solid line of the same color below 
the Tcra/d map. (B) Schematic representation of homozygous deleted 
areas (defined by Log2[tumor/kidney] ratio < 1.6) within the Tcra/d 
locus for ATM-deficient thymic lymphomas. Each line represents the  
deleted region in one of the 20 independent tumors analyzed. The  
analysis includes the six tumor samples shown in A. The asterisks mark 
two tumors that deleted C based on CGH (also shown in Fig. 1 C).1374 Genomic changes in ATM-deficient thymic lymphomas | Zha et al.
sequences situated just centromeric of the chromosome 12 
deletion in particular tumors and the other came from the 
D/J area on chromosome 14. By this approach, we were 
able to isolate and sequence putative PCR translocation junc­
tion products from two tumors (8102 and 8174; Fig. 4 B). In 
both cases, the chromosome 14 side of the junction was adja­
cent to a canonical RSS sequence within the Tcrd locus and, 
in one case, the junction included a potential P element   
(Fig. 4 B; P element in green and underlined), strongly indicat­
ing that these translocations derived from DSBs generated 
during V(D)J recombination. However, the two putative chromo­
some 12 breakpoints, which were 10 Mb apart, were rather 
unremarkable. There was no evidence of a cryptic RSS in this 
region. The next known coding transcripts on chromosome 12 
(predicted by mouse genome version mm8) are 30 kb (8174) 
and 752 kb (8102) away from the breakpoints.
The Tcra/d and Igh Loci often lie in close proximity  
in thymocytes
ATM is required for normal end­joining during V(D)J re­
combination at both the Igh locus in developing B cells and 
the Tcra/d locus in developing T cells, and ATM is also re­
quired  to  mediate  checkpoints  that  eliminate  developing 
ATM­deficient B and T cells with breaks at their antigen re­
ceptor loci (Liyanage et al., 2000; Callén et al., 2007; Huang 
et  al.,  2007).  Correspondingly,  developing  B  and  T  cells 
sometimes suffer unrepaired V(D)J recombination associated 
DSBs at their Igh or Tcra/d loci, respectively, that persist and   
can be substrates for translocations (Callén et al., 2009). In this 
regard, developing T lymphocytes frequently undergo D to J 
rearrangements at their Igh loci (Züñiga et al., 1982). Thus, 
the frequent occurrence of unrepaired V(D)J recombination–
associated DSBs at the Igh and Tcra/d loci in the progenitors 
of ATM­deficient thymic lymphomas may be a major con­
tributor to the frequent occurrence t(12;14) translocations in 
ATM­deficient thymic lymphomas. Indeed, t(12;14) transloca­
tions have been observed in nonmalignant ATM­deficient 
peripheral T cells (Liyanage et al., 2000; Callén et al., 2007, 
2009). Loci that are frequently broken in normal cells have, 
in some cases, been found to translocate at very high fre­
quency (Wang et al., 2009); and such high frequency translo­
cations have been found to also correlate with close proximity 
of the loci in the interphase nucleus (Wang et al., 2009).   
To further explore the latter possibility, we used interphase 
3D FISH to assay the proximity of the Tcra/d and Igh loci in 
the interphase nucleus of thymocytes. Although we found 
only 1% of Tcra/d and Igh loci colocalized at a resolution of 
0.5 µm (Fig. S7, A–E), we found that Tcra/d colocalized with 
Igh in 12–19% of thymocytes (Fig. S7, A–E) when measured 
at a resolution of 1 µm, which appeared significant as only   
4–5% of thymocytes showed colocalization of their two 
Tcra/d loci and <1% of thymocytes showed colocalization   
of their two Igh loci at the 1­µm level of resolution (Fig. S7, 
A–E). Thus, the frequent proximity of the Igh and Tcra/d  
loci in total thymocytes is consistent with proximity also 
playing a role in promoting recurrent t(12;14) translocations. 
experimental backgrounds has been implicated as a haplo­
insufficient tumor suppressor in mice (Kamimura et al., 2007) 
and which has been found to be involved in translocations in 
human T­ALL (MacLeod et al., 2004; Przybylski et al., 2005; 
Su et al., 2006), is deleted from the chromosome 12 involved 
in the t(12;14) translocations in 21 of 23 ATM­deficient thy­
mic lymphomas we characterized (Fig. 4 A). In this context, 
array­based expression analyses of three ATM­deficient thy­
mic lymphomas showed apparently reduced Bcl11b expres­
sion levels (15–30% of WT thymocyte levels; Fig. S6 C)
To gain further insight into molecular mechanisms that 
lead  to  the  recurrent  t(12;14)  translocations  in  Atm/  
thymic lymphomas, we further analyzed the CGH data and 
designed sets of PCR primers that might amplify transloca­
tion junctions. One primer in a given set derived from   
Figure 4.  The t(12;14) translocations in Atm/ thymic lympho-
mas have junctions within a broad telomeric region of chromosome 
12. (A) CGH mapping of the centromeric boundary of hemizygous dele-
tions at the telomeric end of chromosome 12 in Atm/ thymic lympho-
mas. A hemizygous deletion is defined by Log2 (tumor/kidney) ratio below 
0.6. The filled diamonds represent Atm/ tumors and the open dia-
monds represent the E/Atm/ tumors. The x axis is marked with the 
base pair position from the centromere of chromosome 12 (according to 
mouse genome mm8). The positions of Tcl1, Bcl11b, and Igh are marked 
by black arrows or boxes. (B) Diagram and sequence of t(12:14) transloca-
tion junctions obtained from two Atm/ thymic lymphomas (8102 and 
8174). Both junctions were independently PCR amplified, cloned (in dupli-
cate), and sequenced from both ends. The arrows on the diagram and 
arrowheads on the sequences indicate the position of the breakpoints in 
chromosomes 14 and 12. In the sequence diagrams, sequences corre-
sponding to germ line chromosome 12 sequences are presented in blue 
and those corresponding to germ line Tcrd sequences (chromosome 14) 
are shown in red. The black letters in junction 8174 indicate nucleotides 
that could not be unequivocally matched to either side of the junction 
(e.g., potential insertions). The underlined, green letters in junction 8102 
(GAT and A) are potential palindromic (P) elements. The canonical RSS 
sequences for the involved J and D segments are underlined.JEM VOL. 207, July 5, 2010 
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and  amplifications  of  the  common  amplification  region 
upstream of Tcra/d locus.
Together, our findings suggest that aberrant resolution of 
DSBs generated during Tcrd V(D)J recombination in ATM­
deficient double­negative thymocytes leads to chromosome 
However, we also must note that it is not yet clear if Igh 
breaks are indeed intermediates in most t(12;14) transloca­
tions in ATM­deficient thymic lymphomas or what the rela­
tive proximity of these two loci is in the actual thymocyte 
progenitors of these tumors.
Atm/E/ mice developed thymic lymphomas with clonal 
translocations involving the Tcrd locus
To test putative roles of E in thymic lymphomagenesis in 
the ATM­deficient background, we generated Atm/E–/ 
mice by crossbreeding mice harboring these mutations. SP 
 T cells are basically absent in Atm/E/ mice (Fig. 5 A), 
which is consistent with the requirement for E for the vast 
majority of V to J rearrangements (Krangel et al., 2004). 
Yet, total thymocyte numbers are increased in Atm/E/ 
mice in comparison to Atm/ mice, potentially suggesting 
aberrant Tcra rearrangement in the absence of ATM might 
contribute to reduced total thymic cellularity in Atm/ mice 
(Fig. 5 A). Notably, Atm/E/ mice still succumbed to 
DP thymic lymphomas with average survival of 103 ± 28 d, 
which is not significantly different from that observed in their 
Atm/ counterpart (119 ± 30 d, P value = 0.65; Fig. 5 BA). 
Cytogenetic analysis of five Atm/E/ thymic lympho­
mas revealed clonal chromosome 14 translocations in all cases 
analyzed (Fig. 5 C), and CGH analyses revealed characteristic 
amplifications and t(12;14) translocations that are indistin­
guishable from those of their Atm/ counterparts (Fig. 5 D), 
indicating that neither E driven Tcra V(D)J recombination 
nor E driven oncogene expression are essential for the gen­
eration of ATM­deficient thymic lymphomas with chromo­
some 14 translocations/amplifications.
DISCUSSION
Most immature T cell lymphomas from ATM­deficient 
mice have a CD4+CD8+ DP phenotype (Barlow et al., 
1996; Borghesani et al., 2000). Thus, these tumors have 
generally been thought to derive from developing thymo­
cytes that attempted and failed to undergo normal Tcra 
gene rearrangement (Liyanage et al., 2000; Callén et al., 
2009). Correspondingly, recurrent chromosome 14–related 
translocations in ATM­deficient mouse thymic lympho­
mas have often been attributed to aberrant Tcra rearrange­
ments and cellular selection for E­mediated oncogene 
overexpression (Liyanage et al., 2000; Callén et al., 2009). 
In contrast to these expectations, we find that the recur­
rent t(12;14) translocations in ATM­deficient thymic lym­
phomas derive from mis­repair of DSBs generated during 
V(D)J recombination at the Tcrd locus. This conclusion is 
indicated by our finding of an intact C region in most 
ATM­deficient thymic lymphomas (Fig. 1 C and Fig. 3) 
and also by our finding of t(12;14) translocations that have 
breakpoints within the Tcrd locus (Fig. 4 B). In this con­
text, although E is required for normal Tcra rearrange­
ment (Sleckman et al., 1997), our findings clearly demonstrate 
that E is not required for development of ATM­deficient 
thymic lymphomas harboring clonal t(12;14) translocations 
Figure 5.  Ea is not required for ATM-deficient thymic lymphoma 
with recurrent translocations and amplifications. (A) FACS analyses  
of CD4 and CD8 expression on WT, Atm/, E/, and Atm/E/  
thymocytes. The number at the top right quadrant of each dot plot  
indicates the percentage of CD4+CD8+ DP T cells in total live thymocytes. 
Surface CD3 levels of gated DP cells (gated on top right quadrant of the 
dot plot) are plotted on the histogram on the right. The total thymocyte 
number (average  ± standard deviation) from at least three mice of each 
genotype (at 4–6 wk of age) is marked in the top right corner of the  
histogram plots. FACS analyses were performed for at least three mice  
of each genotype independently, and representative plots are shown.  
(B) Survival analysis of Atm/E/ mice and littermate control Atm/ 
and E/ mice. (C) Representative chromosome paints and FISH  
analyses show t(12:14) translocations involving the Tcra/d locus in one  
Atm/E/ thymic lymphoma (6099). The red arrow indicates the normal 
chromosome 14 and the arrowhead indicates the t(12;14) translocations. 
Similar results were obtained for all five Atm/E/ thymic lymphomas 
analyzed. 20 metaphases were analyzed from each tumor, and >80% of 
the metaphases from each tumor had the clonal t(12;14) translocation. 
(D) Representative CGH analyses of Atm/E/ thymic lymphoma DNA. 
CGH analyses were performed once for each tumor. The analysis shown is 
for DNA from tumor 5696 and is representative of the results from CGH 
analyses of five Atm/E/ thymic lymphomas. The y axis is amplifica-
tion/deletion index (LN tumor/kidney ratio of each tumor analyzed). The x 
axis depicts the 20 mouse chromosomes as indicated (1–19 plus chromo-
some x and y and centromere to telomere). Red arrows and text indicate 
recurrent amplifications of sequences corresponding to the Notch1 and 
Chr14amp probes, as well as trisomy of chr 15 (Tric15). The black arrows 
and text indicates the various TCR loci. The green arrow and text indicates 
recurrent deletions in the telomeric portion of chromosome 12 (tch12).1376 Genomic changes in ATM-deficient thymic lymphomas | Zha et al.
respectively. The fact that the vast majority of the genomic 
sequence of human chromosome 14 maps either to mouse 
chromosomes 12 or 14 (Fig. S1) suggests that there may po­
tentially be selection of a common target with respect to the 
human inv(14) or t(14;14) and mouse t(12;14) translocations 
(Liyanage et al., 2000; Callén et al., 2009; Fig. 2, Fig. S1,   
Fig. S4, and Table S1). One obvious candidate was TCL1, the 
proposed oncogenic target of the common inv(14)(q11;q32) 
or t(14;14)(q11;32.1) (Fig. S1) in T­PLL from AT patients 
(Russo et al., 1989). TCL1 maps to human chromosome 
14q32 and to a position 105 Mb telomeric to the centromere 
of mouse chromosome 12 (Fig. 4 A and Fig. S1). The simple 
hypothesis would be that the recurrent t(12;14) translocations 
in mice might activate Tcl1 on chromosome 12 and be   
positively selected for transformation (Pekarsky et al., 2001). 
However, Tcl1 is often deleted in the t(12;14) translocations 
(Fig. 4 A; Liyanage et al., 2000), and we do not find TCL1 
overexpression  in  ATM­deficient  thymic  lymphomas   
(Fig. S5 B). Although there may be other chromosome 12 
oncogenes activated via the recurrent t(12;14) translocations, 
this possibility seems unlikely given that the chromosome 12 
junctional region of the t(12;14) translocations occur at various 
positions within a 28­Mb region, regardless of whether the 
tumors are from cells in which E was present or absent   
(Fig. 4 A). An alternative possibility is that the t(12;14) trans­
locations might result in hemizygous loss of a putative tumor 
suppressor gene that lies somewhere near the telomeric end 
of chromosome 12. In this regard, it is notable that one copy 
of Bcl11b, a putative haploinsufficient tumor suppressor in 
p53+/ mouse thymic lymphomas (Kamimura et al., 2007) 
and potentially also in human T­ALLs (MacLeod et al., 2004, 
2008; Przybylski et al., 2005; Su et al., 2006) is deleted in the 
context of the t(12;14) translocations in the vast majority   
(21 of 23) of the mouse Atm/ thymic lymphomas. As 
might be expected, we observed reduced expression of Bcl11b 
and several other genes in the deleted region in a subset of   
tumors analyzed (Fig. S6 C).
Another possibility is that t(12:14) translocation in mouse 
ATM­deficient thymic lymphomas might not directly con­
tribute to oncogenic transformation but, instead, may reflect 
a high frequency of the corresponding translocation in tumor 
progenitor cells caused by mechanistic factors. Such mecha­
nistic factors could include the occurrence of frequent unre­
paired RAG­initiated breaks in the Tcra/d and Igh loci in 
developing thymocytes (Callén et al., 2007, 2009; Huang   
et al., 2007) and, potentially, the relative proximity of these 
two loci in total thymocytes (Fig. S7). In this regard, the 
ATM­deficient background would also promote persistence 
and frequent translocation of such DSBs (Callén et al., 2007). 
Although the t(12;14) junctions are spread over a large (28­
Mb) area downstream of Igh (Fig. 4 A), it is still conceivable 
that some or all of them were initiated by RAG JH region 
DSBs, given findings that persistence of such Igh DSBs in   
developing ATM­deficient developing B cells persist often   
leads to substantial levels of downstream chromosomal se­
quence loss before they enter into translocations in mature   
14 breaks that are aberrantly repaired in the absence of 
ATM, thereby leading both to recurrent gene amplifications 
on chromosome 14 and translocations involving chromosome 
14 and 12. We note that mechanisms we describe for generating 
these recurrent forms of genomic instability in ATM­deficient 
mouse thymic lymphomas, to date, appear uniquely associated 
with ATM deficiency. Thus, a series of previously characterized 
thymic lymphomas that arise in other mutant backgrounds 
(e.g., Notch­ICN overexpression, p53 deficiency, H2AX/p53 
deficiency, etc.) lack recurrent amplifications of chromosome 
14 sequence and recurrent chromosome 14 or 12 translocations 
(Bassing et al., 2003, 2008; Li et al., 2008; Giblin et al., 2009). 
Conceivably, the recurrent translocations found in ATM­
  deficient thymocytes are associated with the unique combina­
tion of checkpoint and V(D)J recombination defects associated 
with ATM deficiency (Callén et al., 2007).
We find that nearly all ATM­deficient thymic lympho­
mas harbor amplifications of a common 500­kb region that 
lies 10 Mb upstream of the Tcra/d locus (Fig. 1 and Fig. S2). 
We further show that this amplification occurs on a residual 
centromeric fragment of chromosome 14 and not on the   
recurrent t(12;14) (Fig. 2 and Fig. S4). The fact that this 
amplification occurs in all 23 tested ATM­deficient thymic 
lymphomas strongly suggests that it may be linked to some 
stage of the oncogenic process that leads to the full­blown 
ATM­deficient thymic lymphomas. The commonly ampli­
fied region is relatively compact and appears to hold 16 
genes (including 10 potential mRNA transcripts, 1 microRNA, 
and several noncoding transcripts according to University   
of California at Santa Cruz genome browser mouse gene   
annotation_2006 Feb version; Fig. S5 A), none of which are 
known oncogenes. At this time, the precise contribution of 
this amplified region (and the amplified sequences that are 
contained within it) to the oncogenic process that generates 
ATM­deficient thymic lymphomas is unknown; although in 
many human tumors, gene amplification is associated with 
tumor progression as opposed to tumor initiation. Indeed, 
other genetic alterations that we describe in ATM­deficient 
thymic lymphoma (e.g., Notch1 mutation, Pten deletion, and 
chromosome 12 deletions) or, potentially, still unknown genetic 
alterations also likely contribute to the generation of these 
tumors. Expression array analyses indicated that 3 of 8 tested 
genes within the common amplification unit were overex­
pressed by 3–10­fold (Fig. S6 B); however, because passenger 
genes within amplicons are also often highly overexpressed 
(Kohl et al., 1983), overexpression does not allow us to pin­
point a potential oncogene within the amplicon. In any case, 
the genes within the amplified region are candidates to test 
for genetic activities that can contribute to thymocyte tumor 
development in mice and, potentially, in humans (see last 
paragrpah of Discussion).
Why is chromosome 12 a frequent partner for chromosome 
14 translocations?
The  most  common  translocations  in  murine  and  human 
ATM­deficient thymic lymphomas, are t(12;14) and t(14;14), JEM VOL. 207, July 5, 2010 
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large chromosome 12 telomeric deletions, which might   
contribute to tumorigenesis, for example, by deletion of a 
tumor suppressor.
Implications for T cell lymphoma in AT patients
Although the mature T cell lymphomas from older AT patients 
contain characteristic translocations between the TCRA/D  
locus and a TCL1 family member (Russo et al., 1989), the 
nature of the potential oncogenic events that contribute to 
the common immature T cell leukemia (T­ALL) in AT pa­
tients is still largely unknown. Developmentally, ATM­deficient 
murine thymic lymphomas resemble the developmental stage 
of human T­ALL. Our current finding of recurrent gene   
amplifications in ATM­deficient mouse thymic lymphomas 
suggests  a  previously  unconsidered  potential  oncogenic 
mechanism (e.g., gene amplification) that may contribute to 
the generation of T­ALLs in human AT patients. In prelimi­
nary studies aimed at further elucidating this possibility, we 
performed CGH array analyses on a T­ALL sample from an 
AT patient, which showed an amplification of sequences   
lying at human chromosome 14q22 (Fig. S3 E), which is the 
region of this human chromosome that corresponds to the 
amplified region we identified in mouse ATM­deficient thymic 
lymphomas. However, because of the unavailability of ap­
propriate materials, we were not able perform a more detailed 
characterization of these human T­ALL samples. Finally, our 
CGH analyses of ATM­deficient mouse T cell lymphomas 
revealed frequent activation of Notch1 (via mutation or am­
plification) and deletion of Pten (Fig. 1 and Fig. S3). Both of   
these events are common in human T­ALL (Weng et al., 2004). 
Therefore, further characterization of the oncogenic events 
leading to ATM­deficient thymic lymphomas, including defini­
tion of the target of the common gene amplification, may 
provide further insights into the etiology of human T­ALLs.
MATERIALS AND METHODS
Mice. We have previously described the ATM­deficient mice used in this 
study  (Borghesani  et  al.,  2000).  To  generate  the  Atm/E/  cohort, 
E/ mice, which we also described previously (Sleckman et al., 1997), 
were bred with Atm+/ mice to generate mice homozygous for both muta­
tions. Animal protocols were approved by the Institutional Animal Care and 
Use Committee of Children’s Hospital Boston.
Southern blotting. Genomic DNA was isolated from tumors or normal 
tissues from control mice, and Southern blotting was performed with 10 µg 
of EcoRI­digested genomic DNA. The C probe was a 438­bp fragment 
derived from intron1 of C, which was prepared via PCR amplification 
from genomic DNA using 5­GAAGTGGCAGAGCATCTCGGTC­3 and 
5­GTGGCATCACAGGGAACGTCTAAA­3 primers. The C probe 
was a 508­bp fragment derived from intron1­exon3 and PCR amplified 
with  5­CCTCTTGCCCTCAGCTTACC­3  and  5­CTTGGCAAA­
CAGCAGTCGTAG­3 primers. The Amp probe is a 916­bp PCR frag­
ment (described in more detail in the Results section) that was generated 
with  5­AAGTGGCCGTGGATACTGA­3 and 5­GTATACAGGTG­
CAGCCGTTAAA­3 primers.
Thymocyte  development.  Thymocyte  populations  were  analyzed  by 
flow cytometry, as previously described (Sleckman et al., 1997; Borghesani 
B cells (Callén et al., 2007, 2009). Finally, we note that there 
is a potential precedent for “mechanistically promoted” re­
current translocations; thus, the translocation of activation­
induced deaminase (AID)–dependent Igh DSBs to RAG­ 
dependent Ig DSBs in NHEJ­deficient peripheral B cells is 
apparently so frequent in tumor progenitors that it leads to 
these translocations recurrently appearing in peripheral B cell 
lymphomas that arise from NHEJ­deficient plus p53­deficient 
B cells (Wang et al., 2008, 2009).
Model for the mechanism of recurrent translocations  
and amplifications in ATM-deficient thymic lymphomas
Based our current findings and the considerations outlined 
above, we propose a working model to explain the transloca­
tions/amplifications  found  in  ATM­deficient  thymocytes 
(Fig. S2). This model is based, in part from the model that we 
proposed to explain the recurrent appearance of complex 
translocations and amplifications, or “complicons,” involving 
the Igh and c-myc loci in NHEJ/p53­deficient pro–B cell 
lymphomas (Zhu et al., 2002). This model proposes that   
Igh/c-myc complicons found in NHEJ/p53 deficient pro–B 
lymphomas arise by a mechanism in which RAG­generated 
Igh breaks on chromosome 12 in NHEJ/p53­deficient mouse 
pro–B cells are fused to chromosome 15 downstream of c-myc 
leading to dicentric chromosomes that promote c-myc ampli­
fication via a breakage­fusion­bridge (BFB) mechanism (Zhu 
et al., 2002). By analogy, in ATM­deficient developing thy­
mocytes, unrepaired Tcrd locus breaks may lead to the gener­
ation of dicentric chromosomes that then go through a BFB 
cycle, facilitated by the checkpoint deficiency associated with 
ATM deficiency to allow amplification of the region up­
stream of Tcra/d (Fig. S2). The fact that most amplicons begin 
within or upstream of Tcrd is consistent with this possibility, as 
sequences proximal to initiating DSBs are sometimes deleted 
during the translocation/amplification process (Zhu et al., 
2002).  Dicentrics  could  be  chromosome  14  fusions  (after 
replication through Tcrd DSBs facilitated by the G1 check­
point deficiency in ATM­deficient cells [Fig. S2]) or fusions 
to DSBs on other chromosomes (Zhu et al., 2002; Rooney 
et al., 2004b). In this regard, in preliminary studies we indeed 
observed an increased frequency of chromosome 14 dicen­
trics  in  IL­7–stimulated  thymocytes  from  ATM­deficient 
mice (freq = 0.95 ± 0.24%) versus WT mice (freq = 0 ± 0%; 
P value = 0.017 by Student’s t test, between WT and Atm/ 
mice; Fig. S7 F). Involved chromosomal breaks outside of 
Tcrd might also be RAG­initiated or they may be generated 
by other factors (Fig. S2). In this model, chromosome 12, 
because of frequent and persistent unrepaired RAG­initiated 
breaks in the ATM­deficient background, might serve either 
as a partner to generate a dicentric or, because of frequent 
breaks and relative proximity, simply as a frequent recipient 
for persistent chromosome 14 breaks generating t(12;14) as a 
mechanistic “passenger” (Wang et al., 2009; Fig. S2). Finally, 
this model would not rule out the possibility that frequent 
chromosome 14 to chromosome 12 translocations that oc­
curred in this context might be selected for those harboring 1378 Genomic changes in ATM-deficient thymic lymphomas | Zha et al.
(Jackson Immuno Research Laboratories) and were used at 1:200 dilution. 
Images of 50 serial optical sections spaced by 0.2 µm were captured with 
Marianas spinning disk confocal microscope (63×) with a charge­coupled 
device detector (Intelligent Imaging Innovations) and analyzed with Slide­
book software (Intelligent Imaging Innovations).
Array CGH analyses. For CGH, 5 µg of genomic DNA from ATM­ 
deficient mouse thymic lymphomas was profiled against 5 µg of matched 
normal kidney DNA from the same mouse. Genomic DNA processing, la­
beling and hybridization to 244k mouse Agilent CGH 60­mer oligo arrays 
was performed at the Arthur and Rochelle Belfer Cancer Genomics Center 
at the Dana­Farber Cancer Institute. Detailed features of the 244k mouse 
genome array can be found at http://www.agilent.com. Fluorescence ratios 
of scanned images were normalized and copy number profiles were gener­
ated  by  circular  binary  segmentation,  which  determines  significance  of 
change  points  in  raw  data  through  permutation  (Olshen  et  al.,  2004). 
Thresholds for copy number alterations were set at log2 = ±0.6 for trisomy 
or hemizygous deletion.
Online supplemental material. Fig. S1 diagrams the syntenic regions of 
human chromosome 14 and mouse chromosomes 12 and 14. Fig. S2 de­
scribes the prior and current models for potential mechanisms and roles of 
chromosome 12 and 14 translocations in ATM­deficient thymic lympho­
mas. Fig. S3 shows the CGH results and Notch1 mutation analyses of ATM­
deficient  T  cell  malignancies.  Fig.  S4  shows  additional  examples  of 
cytogenetic analyses of ATM­deficient thymic lymphomas. Fig. S5 describes 
that t(12;14) translocations in ATM­deficient thymic lymphomas are associ­
ated with deletion of telomeric sequence of chromosome 12, but not over­
expression of TCL1. Fig. S6 describes the genes amplified or deleted in 
recurrent translocations in ATM­deficient thymic lymphomas. Fig. S7 elu­
cidates the spatial colocalization of the Igh and Tcra/d loci in thymocytes. 
Tables S1–3 presents the summary of cytogenetic analysis of ATM­deficient 
thymic  lymphomas.  Online  supplemental  material  is  available  at  http://
www.jem.org/cgi/content/full/jem.20100285/DC1.
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